Can Routine Data be used to Determine the Target Population of Patients with Type 2 Diabetes in Early Benefit Assessments in Germany?
Corinna ten Thoren,Anja Schwalm,Sarah Mostardt,Dietmar Weber,Peter Ihle,Lutz Altenhofen · Das Gesundheitswesen · 2020 · Heft S 1 · S. S13 bis S19
Bibliografische Angaben
Zusammenfassung
Abstract Objectives Since 2011, early benefit assessment of all new drugs launched in Germany is mandatory. The exact determination of the appropriate target population (i.e. patients eligible for a drug) plays an important role for subsequent price negotiations. In type 2 diabetes, the size of the target population varies considerably between company dossiers submitted for assessment. Our aim was to explore whether routine data from all persons insured in German statutory health insurance (SHI) funds can be used to derive information on the size of the target population with type 2 diabetes. Methods We explored…
